Bernard Parker is Chief Business Officer at SPHBio, where he leads the company’s full range of dealmaking and partnering activities focused on licensing, collaborations, and M&A. Bernard is a biopharmaceuticals executive with more than 20 years of corporate development, overall corporate pipeline/R&D strategy, commercialization, and business operations expertise at small biotech and large multinational pharmaceutical companies. He has a proven ability to forge alliances and deliver global perspective across a range of stakeholders in worldwide, multicountry, and national roles. Bernard has held influential leadership positions at companies such as Novartis, Ionis Pharmaceuticals, Akcea Therapeutics, and Amgen Oncology in roles based in the US, Germany, and Switzerland. Bernard’s experience includes strategic and operational roles in programs ranging from preclinical and clinical development through commercial launch across drug modalities and therapeutic areas including oncology, rare disease, neurology, cardiology, and liver disease. Earlier in his career, Bernard was a management consultant at Bain & Company, and he also conducted biomedical research at the National Institutes of Health. He currently serves on the Board of Directors of Biocom California and the Industry Advisory Council of UC San Diego Moores Cancer Center. Bernard earned a bachelor’s degree in Biology from Hampton University and an MBA from Harvard Business School.